Skip to main content

December 2016

 

 

academics

 

Clinical research courses

Recruitment for Pharmacists & Scientific Assistant at Tata Memorial Centre - 03 posts | B.Pharm may apply

The Tata Memorial Centre (TMC) is a Comprehensive Cancer Centre with a mission to achieve the highest standards in patient care, cancer prevention, cancer research and professional development for oncology and allied disciplines. TMC is an autonomous body funded, controlled by the Department of Atomic Energy, Government of India. TMC is affiliated to Homi Bhabha National Institute (HBNI). The HBNI is a Deemed University of the Department of Atomic Energy with a mission to develop high quality postgraduate educational programs in science and technology including those related to life and health sciences. An exclusive state-of-the-art Homi Bhabha Cancer Hospital & Research Centre (HBCH&RC) is being built by Tata Memorial Centre at Aganampudi, Vishakhapatnam and it has a mandate to develop into National Centre of Excellence dedicated to Service, Education and Research in Cancer. This hospital facility is likely to be fully commissioned in 2018 as a full fledged Cancer Care Centre. TMC invites applications from eligible candidates of Indian nationality, who are keen to pursue a career in TMC. Full time positions in various departments available in HBCH&RC, Vizag are listed below:

Post : PHARMACIST ‘B’ : (02 UR), SCIENTIFIC ASSISTANT ‘B’ (RADIO-DIAGNOSIS)

Job for Research Scientist at Industrial Research and Consultancy Centre - IIT | Salary upto 50 - 70,000 per month

The Industrial Research and Consultancy Centre (IRCC) co-ordinates and facilitates all research and development activities at the Institute.IIT Bombay is a premier educational and research institute. IIT Bombay is pursuing research that makes a difference.

Post : Research Scientist

Career in Demand Drug and Consumables as Consultant at HMSCL

Applications are invited for filling up following posts on contract basis and initially upto 31st March, 2017, extendable further on requirement. The required academic qualifications, experience, remuneration and other conditions are as below:-

Walk in for QC Executives & Production Operators at Hetero Drugs | 50 posts

HETERO, research based approved USFDA, TGA, EU, PMDA, KFDA and WHO global pharmaceutical company established in 1993, focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages.

Post: QC Executives & Production Operators

Job for Post Doctoral Fellow, Research Associate, SRF, JRF at CCMB

The Centre for Cellular and Molecular Biology (CCMB) is one of the constituent national laboratories of the Council of Scientific & Industrial Research (CSIR) and a premier scientific institute that conducts high quality research in frontier and multi-disciplinary areas of modern biology.

Walk-in for QC, QA, Engineering at IPCA LAB | 35 Openings

Ipca has been continuously evolving as an integrated pharmaceutical company over 65 years. Ipca has an annual turnover in excess of Rs.3,120 Crores with over 350 formulations and 80 APIs for various therapeutic segments. We are committed to Research & Development and expanding our R&D capabilities to build a strong future. cGMP (current Good Manufacturing Practices) & Safety is a way of life. We are committed to further enhance cGMP and safety journey on continuous basis to deliver safe and quality products for mankind and to build a safe workplace for our employees. Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

Post : QC, QA, Engineering

Job for Professors, Associate Professor, Assistant Professor at Anurag Pharmacy College

Anurag Pharmacy College, is one of the best rural pharma colleges with more emphasis on learning through experience and active research orientation. The college is reputed for the professional approach in pharma education and is looking for self motivated and well qualified faculty who can prepare students for the next generation careers.

Soligenix, Inc.,  a late-stage biopharmaceutical company, announced SGX942 (dusquetide) has been granted Promising Innovative Medicine (PIM) designation in the United Kingdom (UK) by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy.

Novartis announced initial topline results from two pivotal phase III clinical studies evaluating the safety and efficacy of pegpleranib in combination with Lucentis (ranibizumab) for the treatment of neovascular age-related macular degeneration (nAMD). Studies OPH1002 and OPH1003, sponsored by Ophthotech Corporation, did not meet the primary endpoint of superiority for the pegpleranib and ranibizumab combination therapy, measured as best corrected visual acuity (BCVA) in terms of additional letter gains over ranibizumab monotherapy. At month 12, patients in the pegpleranib and ranibizumab combination treatment groups showed a 10.74 letter BCVA improvement in study OPH1002 and a 9.91 letter BCVA improvement in study OPH1003. Patients treated with ranibizumab alone showed a 9.82 letter BCVA improvement in the OPH1002 study and a 10.36 letter BCVA improvement in the OPH1003 study.